tetano
Editor, Senior Moderator
Transplantation
. 2022 Jun 28.
doi: 10.1097/TP.0000000000004256. Online ahead of print.
Factors Associated With COVID-19 Vaccine Response in Transplant Recipients: A Systematic Review and Meta-analysis
Jiajing Li[SUP] 1 [/SUP], Ibrahim Ayada[SUP] 1 [/SUP], Yining Wang[SUP] 1 [/SUP], Caroline M den Hoed[SUP] 1 2 [/SUP], Nassim Kamar[SUP] 3 [/SUP], Maikel P Peppelenbosch[SUP] 1 [/SUP], Annemarie C de Vries[SUP] 1 [/SUP], Pengfei Li[SUP] 1 [/SUP], Qiuwei Pan[SUP] 1 2 [/SUP]
Affiliations
Abstract
Background: The rapid development and universal access to vaccines represent a milestone in combating the coronavirus disease 2019 (COVID-19) pandemic. However, there are major concerns about vaccine response in immunocompromised populations in particular transplant recipients. In the present study, we aim to comprehensively assess the humoral response to COVID-19 vaccination in both orthotopic organ transplant and allogeneic hematopoietic stem cell transplant recipients.
Methods: We performed a systematic review and meta-analysis of 96 studies that met inclusion criteria.
Results: The pooled rates of seroconversion were 49% (95% confidence interval [CI], 43%-55%) in transplant recipients and 99% (95% CI, 99%-99%) in healthy controls after the second dose of vaccine. The pooled rate was 56% (95% CI, 49%-63%) in transplant recipients after the third dose. Immunosuppressive medication is the most prominent risk factor associated with seroconversion failure, but different immunosuppressive regimens are associated with differential outcomes in this respect. Calcineurin inhibitors, steroids, or mycophenolate mofetil/mycophenolic acid are associated with an increased risk of seroconversion failure, whereas azathioprine or mammalian target of rapamycin inhibitors do not. Advanced age, short interval from receiving the vaccine to the time of transplantation, or comorbidities confers a higher risk for seroconversion failure.
Conclusions: Transplant recipients compared with the general population have much lower rates of seroconversion upon receiving COVID-19 vaccines. Immunosuppressants are the most prominent factors associated with seroconversion, although different types may have differential effects.
. 2022 Jun 28.
doi: 10.1097/TP.0000000000004256. Online ahead of print.
Factors Associated With COVID-19 Vaccine Response in Transplant Recipients: A Systematic Review and Meta-analysis
Jiajing Li[SUP] 1 [/SUP], Ibrahim Ayada[SUP] 1 [/SUP], Yining Wang[SUP] 1 [/SUP], Caroline M den Hoed[SUP] 1 2 [/SUP], Nassim Kamar[SUP] 3 [/SUP], Maikel P Peppelenbosch[SUP] 1 [/SUP], Annemarie C de Vries[SUP] 1 [/SUP], Pengfei Li[SUP] 1 [/SUP], Qiuwei Pan[SUP] 1 2 [/SUP]
Affiliations
- PMID: 35761439
- DOI: 10.1097/TP.0000000000004256
Abstract
Background: The rapid development and universal access to vaccines represent a milestone in combating the coronavirus disease 2019 (COVID-19) pandemic. However, there are major concerns about vaccine response in immunocompromised populations in particular transplant recipients. In the present study, we aim to comprehensively assess the humoral response to COVID-19 vaccination in both orthotopic organ transplant and allogeneic hematopoietic stem cell transplant recipients.
Methods: We performed a systematic review and meta-analysis of 96 studies that met inclusion criteria.
Results: The pooled rates of seroconversion were 49% (95% confidence interval [CI], 43%-55%) in transplant recipients and 99% (95% CI, 99%-99%) in healthy controls after the second dose of vaccine. The pooled rate was 56% (95% CI, 49%-63%) in transplant recipients after the third dose. Immunosuppressive medication is the most prominent risk factor associated with seroconversion failure, but different immunosuppressive regimens are associated with differential outcomes in this respect. Calcineurin inhibitors, steroids, or mycophenolate mofetil/mycophenolic acid are associated with an increased risk of seroconversion failure, whereas azathioprine or mammalian target of rapamycin inhibitors do not. Advanced age, short interval from receiving the vaccine to the time of transplantation, or comorbidities confers a higher risk for seroconversion failure.
Conclusions: Transplant recipients compared with the general population have much lower rates of seroconversion upon receiving COVID-19 vaccines. Immunosuppressants are the most prominent factors associated with seroconversion, although different types may have differential effects.